Combination therapy before surgery for high-risk liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether a combination of two drugs (tislelizumab and lenvatinib) given before surgery can lower the risk of liver cancer coming back in people with early-stage but high-risk disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- Your liver cancer must be at a stage where surgery is possible, and it must be considered high risk for coming back.
- You must have good liver function (Child-Pugh class A) and be in generally good physical condition (ECOG 0-1).
- Your blood counts, kidney function, and other lab tests must be within certain limits.
- You cannot have had any prior cancer treatment for this liver cancer, such as chemotherapy, radiation, or targeted therapy.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving a combination of two drugs—tislelizumab (an immunotherapy that helps your immune system fight cancer) and lenvatinib (a targeted therapy that blocks tumor growth)—before surgery can improve outcomes for people with early-stage liver cancer (a single tumor 2-5 cm) when the surgery is likely to have a narrow margin. You would receive the drugs for a few weeks before your scheduled surgery, and then have the surgery as planned. This approach may help reduce the chance of the cancer coming back.
This trial tests whether giving a combination of two immunotherapy drugs before surgery can lower the chance of liver cancer coming back in people who have high-risk features. It may help patients with early-stage liver cancer that can be removed surgically.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus lenvatinib (a targeted therapy) given before surgery for hepatocellular carcinoma (a type of liver cancer). The goal is to see if this treatment can shrink tumors and reduce the chance of cancer coming back after surgery.
This trial tests whether a combination of two therapies—targeted chemotherapy delivered directly to the liver (TACE) plus immunotherapy (atezolizumab) and a targeted drug (bevacizumab)—can keep liver cancer from coming back after surgery. It is for people whose tumors can be surgically removed but are at high risk of recurrence.
This trial tests whether giving a combination of chemotherapy, immunotherapy, and targeted therapy before surgery can shrink liver cancer and reduce the chance of it coming back, compared to going straight to surgery. The treatment includes medicines like pembrolizumab (sintilimab) and a drug that blocks blood vessel growth (bevacizumab).
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.